Drug Trial Radar · NCT03370133
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
567
Actual
Start
Dec 6, 2017
Primary completion
Jan 8, 2019
Study completion Dec 13, 2019
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Dec 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Conditions
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Psoriatic Arthritis
Interventions
BimekizumabDrug
Bimekizumab will be provided at pre-specified time intervals.
UstekinumabDrug
Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
PlaceboOther
Subjects will receive Placebo at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16Time frame: Week 16
- Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16Time frame: Week 16
Locations
105 sites in 11 countries. Site status is shown where the registry gives one.
Ps0009 946
Phoenix, Arizona
Ps0009 910
Bakersfield, California
Ps0009 919
San Diego, California
Ps0009 906
Boca Raton, Florida
Ps0009 909
Boynton Beach, Florida
Ps0009 912
Coral Gables, Florida
Ps0009 907
Miami, Florida
Ps0009 903
Ocala, Florida
Ps0009 921
Ormond Beach, Florida
Ps0009 918
Tampa, Florida
Ps0009 941
Alpharetta, Georgia
Ps0009 911
Plainfield, Indiana
Ps0009 900
West Des Moines, Iowa
Ps0009 905
Overland Park, Kansas
Ps0009 922
Baton Rouge, Louisiana
Ps0009 917
Troy, Michigan
Ps0009 915
St Louis, Missouri
Ps0009 958
Omaha, Nebraska
Ps0009 901
Portsmouth, New Hampshire
Ps0009 908
East Windsor, New Jersey
Ps0009 923
Albuquerque, New Mexico
Ps0009 913
New York, New York
Ps0009 920
Portland, Oregon
Ps0009 924
Houston, Texas
Ps0009 914
San Antonio, Texas
Ps0009 004
Fremantle, Australia
Ps0009 005
Phillip, Australia
Ps0009 002
Westmead, Australia
Ps0009 009
Woolloongabba, Australia
Ps0009 050
Brussels, Belgium
Ps0009 052
Liège, Belgium
Ps0009 051
Loverval, Belgium
Ps0009 673
Halifax, Canada
Ps0009 652
Oakville, Canada
Ps0009 651
Richmond Hill, Canada
Ps0009 650
Surrey, Canada
Ps0009 653
Toronto, Canada
Ps0009 657
Waterloo, Canada
Ps0009 218
Bonn, Germany
Ps0009 209
Darmstadt, Germany
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.